Part 5: Myelodysplastic syndromes-Treatment of high-risk disease.
作者信息
Magalhães Silvia Maria Meira, Chauffaille Maria de Lourdes Lopes Ferrari, Velloso Elvira Deolinda Rodrigues Pereira, Buzzini Renata, Bernardo Wanderley Marques
机构信息
Hospital Universitário Walter Cantídio, Universidade Federal do Ceará (HUWC UFC), Fortaleza, CE, Brazil.
Escola Paulista De Medicina da Universidade Federal de São Paulo (EPM Unifesp), São Paulo, SP, Brazil; Grupo Fleury, São Paulo, SP, Brazil.
出版信息
Hematol Transfus Cell Ther. 2018 Jul-Sep;40(3):278-282. doi: 10.1016/j.htct.2018.05.013. Epub 2018 Jul 27.
Abstract
摘要
相似文献
1
Part 5: Myelodysplastic syndromes-Treatment of high-risk disease.
Hematol Transfus Cell Ther. 2018 Jul-Sep;40(3):278-282. doi: 10.1016/j.htct.2018.05.013. Epub 2018 Jul 27.
2
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.
3
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Clin Cancer Res. 2004 Nov 15;10(22):7599-606. doi: 10.1158/1078-0432.CCR-04-0598.
4
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.
Blood Rev. 2019 Mar;34:16-25. doi: 10.1016/j.blre.2018.10.002. Epub 2018 Oct 28.
5
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.
6
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.
7
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Lancet Haematol. 2015 Jun;2(6):e260-6. doi: 10.1016/S2352-3026(15)00067-8. Epub 2015 May 20.
8
Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Haematologica. 2015 Apr;100(4):472-8. doi: 10.3324/haematol.2014.112755. Epub 2015 Jan 30.
9
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
10
Smoking and myelodysplastic syndromes.
Epidemiology. 2000 May;11(3):285-91. doi: 10.1097/00001648-200005000-00010.
本文引用的文献
1
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
J Clin Oncol. 2017 Jul 1;35(19):2157-2164. doi: 10.1200/JCO.2016.70.7349. Epub 2017 May 2.
2
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
3
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.
Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.
4
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17.
5
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
J Clin Oncol. 2016 Jun 1;34(16):1864-71. doi: 10.1200/JCO.2015.65.0515. Epub 2016 Apr 4.
6
Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Leuk Res. 2015 Apr;39(4):424-8. doi: 10.1016/j.leukres.2015.01.014. Epub 2015 Feb 12.
7
Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12.
8
Understanding GRADE: an introduction.
J Evid Based Med. 2013 Feb;6(1):50-54. doi: 10.1111/jebm.12018.
9
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
Cancer Sci. 2012 Oct;103(10):1839-47. doi: 10.1111/j.1349-7006.2012.02386.x. Epub 2012 Sep 14.
10
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.
Zotero 插件